• OPEN AN ACCOUNT
Indian Indices
Sensex
83,919.71 897.96
( 1.08%)
Global Indices
Nasdaq
49,248.22 -970.95
(-1.93%)
Dow Jones
7,218.05 -126.58
(-1.72%)
Hang Seng
56,657.02 -2,787.19
(-4.69%)
Nikkei 225
10,369.59 -83.09
(-0.79%)
Forex
USD-INR
93.42 -0.12
(-0.13%)
EUR-INR
102.53 -0.37
(-0.36%)
GBP-INR
123.02 -0.43
(-0.35%)
JPY-INR
0.59 0.00
(-0.15%)

EQUITY - MARKET SCREENER

HCL Infosystems Ltd
Industry :  Computers - Hardware
BSE Code
ISIN Demat
Book Value()
500179
INE236A01020
-10.0494544
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HCL-INSYS
0
310.44
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Max Healthcare, Apollo Hospitals surge as brokerage upgrades boost sentiment
Nov 20,2026
Max Healthcare surged 4.75% to Rs 1,087.60, while Apollo Hospitals jumped 3.94% to Rs 9,089.50. The broker cited improving earnings prospects and more attractive valuations.

The brokerage believes consensus earnings estimates for the hospital sector have bottomed out, while valuations have moderated. It also expects the initial profitability pressure from the ongoing bed expansion cycle to be largely reflected in stock prices. Newly added capacity is ramping up at a healthy pace, supporting the earnings outlook.

The brokerage raised its price target for Max Healthcare to Rs 1,450 from Rs 825, implying an upside of around 33.32% from current levels. It favours the company for its disciplined capital allocation, stronger EBITDA growth outlook and more favourable capacity expansion trajectory.

Max Healthcare is expected to report a compound annual growth rate (CAGR) of 20% in revenue and 22% in EBITDA between FY26 and FY29.

The price target for Apollo Hospitals was increased to Rs 10,500 from Rs 6,230, indicating an upside of around 15.5% from current levels.

However, the brokerage flagged risks to the sector's outlook, including the possibility of the Supreme Court extending price caps beyond oncology drugs and a larger-than-expected profitability drag from newly commissioned hospitals.

For Max Healthcare, a higher share of institutional patients could dilute revenue per patient. For Apollo Hospitals, rising costs associated with its round-the-clock operations could constrain margin expansion in its HealthCo business.